Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.

Journal for immunotherapy of cancer - 1 Sept 2023

Molvi Zaki, Klatt Martin G, Dao Tao, Urraca Jessica, Scheinberg David A, O'Reilly Richard J

Abstract excerpt

BACKGROUND: Certain phosphorylated peptides are differentially presented by major histocompatibility complex (MHC) molecules on cancer cells characterized by aberrant phosphorylation. Phosphopeptides presented in complex with the human leukocyte antigen HLA-A*02:01 provide a stability advantage over their non-phosphorylated counterparts. This stability is thought to contribute to enhanced immunogenicity. Whether...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Histocompatibility Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-A Antigens

Share to HLA-C Antigens

Share to Immunotherapy

Share to Major Histocompatibility Complex

Share to Neoplasms

Share to Phosphopeptides

Source

Open in PubMed Open full text

Identifiers

PMID: 37775115
DOI: 10.1136/jitc-2023-006889
PMCID: PMC10546156

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.PMID 37775115Read ↗

The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA allelesSemantic proximity Read ↗

Mass spectrometry based immunopeptidomics leads to robust predictions of phosphorylated HLA class I ligandsSemantic proximity Read ↗

Deciphering the landscape of phosphorylated HLA-II ligandsSemantic proximity Read ↗

Mass Spectrometry Based Immunopeptidomics Leads to Robust Predictions of Phosphorylated HLA Class I LigandsSemantic proximity Read ↗

Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.Semantic proximity Read ↗

Molecular mechanism of phosphopeptide neoantigen immunogenicitySemantic proximity Read ↗

Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo.Semantic proximity Read ↗

Human Tumor Antigens Yesterday, Today, and TomorrowSemantic proximity Read ↗

Proteogenomic analysis unveils the HLA Class I presented immunopeptidome in melanoma and EGFR mutant lung adenocarcinomaSemantic proximity Read ↗

Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificitySemantic proximity Read ↗

Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificitySemantic proximity Read ↗

Current perspectives on mass spectrometry-based immunopeptidomics: the computational angle to tumor antigen discoverySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.